Assessment and Development of the Antifungal Agent Caspofungin for Aerosolized Pulmonary Delivery
Invasive Pulmonary Aspergillosis (IPA) and <i>Pneumocystis jiroveci</i> Pneumonia (PCP) are serious fungal pulmonary diseases for immunocompromised patients. The brand name drug CANCIDAS<sup>®</sup> (Caspofungin acetate for injection) is FDA approved to treat IPA, but is only...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/4/504 |